United States
                       Securities and Exchange Commission
                              Washington, DC 20549

                                   FORM 10-QSB

                  Quarterly Report Under Section 13 or 15(d) of
                       the Securities Exchange Act of 1934


For the Quarter Ended                                     Commission File Number
September 30, 2003                                                       0-50218


                            EMPS RESEARCH CORPORATION
                            -------------------------
             (Exact name of registrant as specified in its charter)

                                      UTAH
          (State or other jurisdiction of incorporation or organization

                                   87-0669131
                                   ----------
                      (I.R.S. Employer Identification No.)


              875 Donnor Way, Unit 705, Salt Lake City, Utah 84108
              ----------------------------------------------------
                    (Address of principal executive offices)

                                 (801) 582-1881
               ---------------------------------------------------
              (Registrant's telephone number, including area code)

         Securities registered pursuant to Section 12 (b) of the Act:

                                      None

         State the number of shares outstanding of each of the registrants
classes of common equity, as of the latest practicable date.

         Common stock, par value $0.001; 3,300,000 shares outstanding as of
November 10, 2003

<PAGE>

                          PART I. FINANCIAL INFORMATION

Item 1.  Financial Statements

                            EMPS RESEARCH CORPORATION
                          (A Development Stage Company)
                                   FORM 10-QSB
                                TABLE OF CONTENTS


PART I -- FINANCIAL INFORMATION

     Item 1.  Financial Statements

               Condensed Balance Sheets (Unaudited) as of
                 September 30, 2003 and December 31, 2002....................3

               Condensed Statements of Operations (Unaudited) for
                 the Three and Nine Months Ended September 30,
                 2003 and 2002 and for the Cumulative Period from
                 January 30, 2001 (Date of Inception) through
                 September 30, 2003..........................................4

               Condensed Statements of Cash Flows (Unaudited) for
                 the Nine Months Ended September 30, 2003 and
                 2002 and for the Cumulative Period from January
                 30, 2001 (Date of Inception) through September
                 30, 2003....................................................5

               Notes to Condensed Financial Statements (Unaudited)...........6

     Item 2.  Managements Discussion and Analysis or Plan of Operation.......9

     Item 3.  Controls and Procedures.......................................12

PART II -- OTHER INFORMATION

     Item 5.  Other Information.............................................12

     Item 6.  Exhibits and Reports on Form 8-K..............................13

     Signatures.............................................................13

                                       2
<PAGE>
<TABLE>
<CAPTION>
EMPS RESEARCH CORPORATION
(A Development Stage Company)
CONDENSED BALANCE SHEETS
(UNAUDITED)
                                                              September 30,            December 31,
                                                                       2003                    2002
----------------------------------------------------------------------------------------------------
<S>                                                            <C>                     <C>
ASSETS

Current Assets
Cash                                                           $     25,014            $     34,437
Prepaid assets                                                        2,336                   3,441
----------------------------------------------------------------------------------------------------

Total Current Assets                                                 27,350                  37,878
----------------------------------------------------------------------------------------------------

Other Assets

Patents and deferred patent costs, net of amortization
  of $539 and $385                                                    2,096                   2,251
----------------------------------------------------------------------------------------------------

Total Other Assets                                                    2,096                   2,251
----------------------------------------------------------------------------------------------------

Total Assets                                                   $     29,446            $     40,129
====================================================================================================


LIABILITIES AND SHAREHOLDERS' EQUITY

Current Liabilities
Accounts payable                                               $      1,687            $        719
Franchise tax payable                                                     -                     100
Deferred revenue                                                     11,175                  11,232
----------------------------------------------------------------------------------------------------

Total Current Liabilities                                            12,862                  12,051
----------------------------------------------------------------------------------------------------

Shareholders' Equity
Common stock; $0.001 par value, 50,000,000
 shares authorized, 3,300,000 and 3,300,000 shares
 issued and outstanding, respectively                                 3,300                   3,300
Additional paid-in capital                                           33,845                  33,845
Deficit accumulated during the development stage                    (20,561)                 (9,067)
----------------------------------------------------------------------------------------------------

Total Shareholders' Equity                                           16,584                  28,078
----------------------------------------------------------------------------------------------------

Total Liabilities and Shareholders' Equity                     $     29,446            $     40,129
====================================================================================================

          The accompanying notes are an integral part of these financial statements.

                                                3
</TABLE>
<PAGE>
<TABLE>
<CAPTION>
EMPS RESEARCH CORPORATION
(A Development Stage Company)
CONDENSED STATEMENTS OF OPERATIONS
(UNAUDITED)

                                                                                                                   For the
                                                                                                                Cumulative
                                                                                                               Period From
                                                                                                               January 30,
                                                                                                             2001 (Date of
                                                                                                                Inception)
                                              For the Three Months Ended     For the Nine Months Ended             through
                                                           September 30,                 September 30,       September 30,
                                        -------------------------------- -----------------------------  ------------------
                                                  2003             2002         2003             2002                2003
<S>                                         <C>              <C>         <C>               <C>                 <C>
Revenue                                     $        -       $        -  $         -       $        -          $        -
---------------------------------------------------------------------------------------------------------------------------

Expenses
General and administrative                       5,771            2,408       11,340            3,284              19,980
Amortization expense                                51               51          154              154                 539
---------------------------------------------------------------------------------------------------------------------------

Total Expenses                                   5,822            2,459       11,494            3,438              20,519
---------------------------------------------------------------------------------------------------------------------------

Net Loss From Operations                        (5,822)          (2,459)     (11,494)          (3,438)            (20,519)

Other Income (Expense)
Grant revenue                                        -           32,244           57           72,136             140,137
Grant expense                                        -          (32,244)         (57)         (72,136)           (140,137)
Interest expense                                     -                -            -               (2)                (42)
---------------------------------------------------------------------------------------------------------------------------

Total expense                                        -                -            -               (2)                (42)
---------------------------------------------------------------------------------------------------------------------------

Net Loss                                    $   (5,822)      $   (2,459) $   (11,494)      $   (3,440)         $  (20,561)
===========================================================================================================================

Net Loss Per Share                          $    (0.00)      $    (0.00) $     (0.00)      $    (0.00)
=======================================================================================================

Weighted Average Common
Shares Outstanding                           3,300,000        3,000,000  $ 3,300,000        3,000,000
=======================================================================================================

                   The accompanying notes are an  integral part of these financial statements.

                                                           4
</TABLE>
<PAGE>
<TABLE>
<CAPTION>
EMPS RESEARCH CORPORATION
(A Development Stage Company)
CONDENSED STATEMENTS OF CASH  FLOWS
(UNAUDITED)

                                                                                                                       For the
                                                                                                                    Cumulative
                                                                                                                   Period From
                                                                                                                   January 30,
                                                                                                                 2001 (Date of
                                                                                                                    Inception)
                                                                                 For the Nine Months Ended             through
                                                                                             September 30,       September 30,
                                                                          --------------------------------  ------------------
                                                                                    2003             2002                2003
------------------------------------------------------------------------------------------------------------------------------
<S>                                                                           <C>             <C>                 <C>
Cash Flows from Operating Activities
Cash from grant                                                               $        -      $    63,028         $   151,312
Cash paid for grant expenses                                                      (2,625)         (65,811)           (140,137)
Cash paid for interest                                                                 -               (2)                (42)
Cash paid for non grant expense                                                   (6,798)          (1,139)            (18,119)
Cash paid for taxes                                                                    -             (100)               (100)
------------------------------------------------------------------------------------------------------------------------------

Cash Used in Operating Activities                                                 (9,423)          (4,024)             (7,086)
------------------------------------------------------------------------------------------------------------------------------

Cash Flows from Financing Activities
Proceeds from sale of common stock                                                     -                -              32,100
------------------------------------------------------------------------------------------------------------------------------

Cash Provided by Financing Activities                                                  -                -              32,100
------------------------------------------------------------------------------------------------------------------------------

Net Change in Cash                                                                (9,423)          (4,024)             25,014

Cash at the Beginning of the Period                                               34,437            6,406                   -
------------------------------------------------------------------------------------------------------------------------------

Cash at the End of the Period                                                 $   25,014      $     2,382         $    25,014
------------------------------------------------------------------------------------------------------------------------------

Reconciliation of Net Loss to Cash
 Used in Operating Activities

Net Loss                                                                      $  (11,494)     $    (3,441)        $   (20,561)
Adjustments to reconcile net loss to
 cash used in operating activities
   Amortization of patent costs                                                      154              154                 539
   Organization costs paid by issunace of common stock                                 -                -                 264
   Impairment of patent                                                                -                -               2,145
   Change in assets and liabilities:
     Due from government grant                                                         -           (9,108)                  -
     Prepaid assets                                                                1,106                -              (2,335)
     Deferred patent costs                                                             -            2,145                   -
     Accounts payable                                                                968            9,437               1,687
     Due to parent                                                                     -              120                   -
     Franchise tax payable                                                          (100)            (100)                  -
     Deferred revenue                                                                (57)          (3,231)             11,175
------------------------------------------------------------------------------------------------------------------------------

Net Cash Used In Operating Activities                                         $   (9,423)     $    (4,024)        $    (7,086)
==============================================================================================================================

Supplemental disclosure of noncash investing and financing activities
Common stock issued for assignment of patents
from former Parent                                                            $        -      $         -         $     2,636
==============================================================================================================================

                       The accompanying notes are an  integral part of these financial statements.

                                                                5
</TABLE>
<PAGE>

EMPS RESEARCH CORPORATION
(A Development Stage Company)
NOTES TO CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)

NOTE 1 - CONDENSED FINANCIAL STATEMENTS

Condensed Interim Financial Statements -- The accompanying unaudited condensed
financial statements include the accounts of EMPS Research Corporation ("the
Company"). These financial statements are condensed and, therefore, do not
include all disclosures normally required by accounting principles generally
accepted in the United States of America. These statements should be read in
conjunction with the Company's most recent annual financial statements for the
years ended December 31, 2002 and 2001, included in the form 10-SB/A filed with
the United States Securities and Exchange Commission on July 1, 2003. In
particular, the Company's significant accounting principles were presented as
Note 1 to the Financial Statements in that report. In the opinion of management,
all adjustments necessary for a fair presentation have been included in the
accompanying condensed consolidated financial statements and consist of only
normal recurring adjustments. The results of operations presented in the
accompanying condensed financial statements are not necessarily indicative of
the results that may be expected for the full year ending December 31, 2003.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation -- EMPS Research Corporation was organized under the laws
of the State of Utah on January 31, 2001 and has elected a fiscal year end of
December 31st. EMPS Corporation ("Parent") formed the Company by giving cash and
patented technology in exchange for all of the issued and outstanding shares of
EMPS Research Corporation. The accompanying financial statements include only
the accounts of EMPS Research Corporation and are not presented on a
consolidated basis with EMPS Corporation which was its Parent Company. At
December 31, 2002 EMPS Corporation owned 91% of the common stock of EMPS
Research Corporation. EMPS Research Corporation was spun-off from EMPS
Corporation effective May 23, 2003. Certificates for the spin-off were issued
July 31, 2003. The 3,000,000 shares of the Company owned by EMPS Corporation
were distributed to shareholders of EMPS Corporation and at that date the
Company is no longer a subsidiary of EMPS Corporation.

Income Taxes -- Due to losses at September 30, 2003, and December 31, 2002 and
2001, no provision for income taxes has been made. There are deferred income
taxes resulting from income and expense items being reported for financial
accounting and tax reporting purposes in different periods. The difference
arises from the accelerating of the write-off of organization costs for
financial statement purposes as compared to amortizing over 60 months for tax
purposes.

Grant revenue recognition -- The Department of Energy (DOE) grant is funded on a
cost reimbursement basis and payments received from the grant are treated as
earned and recognized as revenue at the time expenditures reimbursable under the
grant are made by the Company. The grant has provisions for advance payments. A
grant receivable is recorded if expenditures exceed amounts received under the
grant and deferred revenue is recorded if payments exceed costs expended under
the grant.

Stock-Based Compensation -- On March 12, 2003 the Company adopted a stock-based
employee compensation plan. The Company will account for the options using the
intrinsic value method in accordance with APB Opinion No. 25, Accounting for
Stock Issued to Employees, and related interpretations.

                                       6
<PAGE>

NOTE 3 - EQUITY TRANSACTIONS

EMPS Research Corporation was spun-off from EMPS Corporation effective May 23,
2003. Stock certificates for the spin-off were issued July 31, 2003. The
3,000,000 shares of the Company owned by EMPS Corporation were distributed to
shareholders of EMPS Corporation and at that date the Company is no longer a
subsidiary of EMPS Corporation.

NOTE 4 - RELATED PARTY TRANSACTIONS

The Company has no employees. As of September 30, 2003 and December 31, 2002 no
compensation was paid or accrued to any officers or directors of the Corporation
due to the fact that it is of only nominal value.

The Company is receiving free office space through a related Party. The value of
the free rent to date has been of nominal value.

The Company decided to abandon its continuation-in-part (CIP) patent application
during the quarter ended September 30, 2002. At December 31, 2001, the costs
associated with this application were recorded as deferred patent costs. After
abandonment, the costs for the CIP patent application were deemed by the Company
to have no future value and the costs were expensed. The total amount paid for
the CIP patent application was $2,145 and was paid in behalf of the Company by
its Parent. The Parent forgave the debt of the $2,145 advanced and the Company
recorded a $2,145 capital contribution.

NOTE 5 - DEPARTMENT OF ENERGY AWARD

The Department of Energy (DOE), through its Office of Industrial Technologies
(OIT) 2000 Inventions and Innovation (I&I) Program awarded a grant to the
Company during 2001. The Company's application was titled "Development of a
High-Frequency Eddy-Current Separator". The grant was approved in the amount of
$199,000.

The grant is a DOE small business grant and thus the Company has no financial
obligation to DOE under the award. The Company is not required to compensate DOE
upon successful (or unsuccessful) commercialization of a prototype (such as for
royalties or commissions). Prior to entering into the award as a small business
concern, the Company had the option to identify technical data that was
proprietary and to elect to retain title to this proprietary data. In so doing
this election, the unlimited right to such technical data by DOE was voided per
DOE regulations. Per DOE regulations if the Company has a "subject invention"
related to work done under the award it can obtain unlimited rights to the
technical data for the "subject invention" and has license to use the invention
only for government use, not commercial use. Even so, if proper application and
reporting is done for the "subject invention" the Company can retain title to
the "subject invention" and the above DOE rights to use the invention or
technical data is void. Management intends to perform the proper reporting and
application process to retain title to any "subject invention" that may arise,
if any, during the course of the award.

The original project period was from February 1, 2001 to January 31, 2003 but
has been extended to December 31, 2003. Research assistance to be conducted
under the grant has been subcontracted to two entities. During the nine months
ended September 30, 2003 the Company incurred grant expenses in the amount of
$72,136. Total grant expenses from inception through September 30, 2003 is
$140,137.

                                       7
<PAGE>

NOTE 6 - STOCK OPTION PLAN

On March 12, 2003, the Board of Directors approved the EMPS Research Corporation
2003 Stock Option Plan (the "Plan"), which allows for the grant of up to
5,000,000 invective stock options or nonqualified stock options. The exercise
price of incentive stock options granted under the Plan will be determined by
the Stock Option Committee of the Board of Directors at the time of grant and
may not be less than 100% of the fair value of the stock. The exercise price of
an incentive stock option granted to a 10% shareholder shall not be less than
110% of the fair value of the stock. Expiration and vesting terms of options
will be determined at the time of the grant. No options have been granted under
the Plan.

NOTE 7 - SUBSEQUENT EVENT

On November 12, 2003, the Company entered into a Private Equity Credit Agreement
with Techgrand Company Limited, a Hong Kong limited company ("Techgrand"), a
current shareholder. Techgrand has agreed to provide the Company an equity
credit line of up to $470,000. Pursuant to the Agreement, the Company can
require Techgrand to purchase restricted common shares of the Company in
increments of $75,000 to $100,000, up to a total of $470,000 worth of restricted
Company common stock at the greater of $0.10 per share, or 85% of the prevailing
market price as defined in the agreement. The Company intends to use these funds
for operational expenses and to further its business activities.

                                       8
<PAGE>

Item 2.  Plan of Operations

         Forward Looking Information and Cautionary Statement

         Certain statements in this quarterly report may be deemed to be
forward-looking statements. Forward-looking statements regarding economic
conditions, effects of corporate initiatives, future profitability, projections,
future revenue opportunities, and their impact on the company are
forward-looking statements and not historical facts. These statements are
estimates or projections involving numerous risks or uncertainties, including
but not limited to, consumer demand, acceptance of products and services offered
by the Company, successful research and development activities, the Company's
ability to control expenses, actions by competitors, changes in market needs and
technology, political or regulatory matters, litigation, general economic
conditions and changes in management strategy.

         Actual results or events could differ materially from those discussed
in the forward- looking statements. See our report on Form 10-SB as filed with
the Securities and Exchange Commission for further information. We disclaim any
obligation to publicly update, revise or correct any forward-looking statements,
whether as a result of new information, future events or otherwise.

         The information contained in this analysis should be read in
conjunction with the financial statements contained herein and related
disclosures.

         Overview

         EMPS Research Corporation (the "Company") was incorporated under the
laws of the state of Utah on January 30, 2001, for the purpose of researching
and developing commercial applications for patented technology for a high
frequency eddy current separator, which may be used to separate nonmagnetic
particulate materials from other materials without chemicals, heat or water. The
Company acquired this patented technology from EMPS Corporation, a Nevada
corporation and formerly the parent of the Company. EMPS Corporation acquired
the technology from Particle Separation Technologies, L.C., a Utah limited
liability company. The Company is in the development stage.

         In February, 2001, the Company acquired Patent No. 5,439,117 issued
August 8, 1995, continuation in part Patent No. 5,772,043 issued June 30, 1998
and continuation in part Patent No. 6,095,337 issued on August 1, 2000. The
three patents are titled "System and Method for Separating Electronically
Conductive Particles." The Company received all right, title and interest in and
to the said inventions and patents in exchange for 1,000,000 restricted common
shares of EMPS Research Corporation valued at the patents' book value of $2,636
and EMPS Corporation provided the Company with $2,100 cash and paid
organizational costs of $264.

                                       9
<PAGE>

         On December 23, 2002, the Company filed an amendment to its Articles of
Incorporation effecting a one for three forward stock split resulting in an
increase of the issued and outstanding common stock from 1,000,000 shares to
3,000,000 shares.

         On May 22, 2003, the board of directors of EMPS Corporation, the former
parent of the Company, recommended undertaking a spin-off distribution to its
shareholders of the 3,000,000 common shares of the Company it held. The spin-off
distribution was to be made in conformity with and in reliance upon the
Securities and Exchange Commission (the "Commission") Staff Legal Bulletin 4,
issued by the Commission on September 16, 1997. Both the management of the
Company and EMPS Corporation were in agreement that the spin-off transaction
would benefit both corporations. Since completing its acquisition of Caspian
Service Group, Ltd in July 2002, the major focus of EMPS Corporation has been
the development of the business operations of Caspian Services Group Ltd.
Caspian Services Group Limited, is engaged in the oil and gas services industry
in the oil rich Kazakhstan sector of the Caspian Sea. EMPS Corporation and the
Company's management agreed that the business focuses of the corporations had
become distinct and each would have greater success in their particular industry
if the Company were no longer a subsidiary of EMPS Corporation.

         Management of EMPS Corporation and the Company each believed that a
spin-off would allow the Company to pursue needed financial investment and
attract management assistance suited for a technology development company if the
spin-off were effected. Each corporation would be able to concentrate attention
and financial resources on its respective business activities, without regard to
the objectives and policies of the other business. As independent businesses
each would be able to offer employee incentives tied directly to the results of
the respective business activities. In addition, the spin-off would allow
investors to better evaluate each business, negotiate financing terms focused on
the distinct activities of each business and thereby improve the likelihood that
each corporation would achieve its objectives.

         On May 23, 2003, the majority shareholders of EMPS Corporation approved
the spin-off distribution. The spin-off distribution was completed on August 6,
2003. EMPS Corporation distributed the 3,000,000 shares of Company common stock
it held to the EMPS Corporation shareholders pro-rata on a one share for ten
basis. The EMPS Corporation shareholders paid no consideration for the Company
common shares they received.

         The Company's business activity is focused on continuing research and
development efforts to develop and test prototype equipment derived from the
patents. The Company has primarily funded its research and development
activities from a research grant awarded to the Company from the Department of
Energy's Office of Industrial Technologies 2000 Inventions and Innovation
program. The research grant was received by the Company in January of 2001 in
the amount of one hundred ninety-nine thousand dollars ($199,000). As of
September 30, 2003, the Company had spent approximately $140,137 of the grant.

                                       10
<PAGE>

         On November 12, 2003, the Company entered into a Private Equity Credit
Agreement with Techgrand Company Limited, a Hong Kong limited company
("Techgrand") whereby Techgrand has agreed to provide the Company an Equity
Credit Line of up to $470,000. Pursuant to the Agreement, the Company can
require Techgrand to purchase restricted common shares of the Company in
increments of $75,000 to $100,000, up to a total of $470,000 worth of restricted
Company common stock at the greater of $0.10 per share or 85% of the prevailing
market price as defined in the Agreement. The Company intends to use these funds
for operational expenses and to further its business activities.

         Plan of Operations

         On or about January 16, 2001, the Company received a research grant in
the amount of $199,000 from the Department of Energy ("DOE"), through its Office
of Industrial Technologies 2000 Inventions and Innovation ("I&I") program for
use in developing an HFECS prototype. The Company recently received approval to
extend the grant period through December 31, 2003.

         Altaire Systems is assisting the Company in designing, fabricating and
assembling the prototype HFECS. Altaire Systems will also be responsible for
field testing and training. Altaire Systems began work on the prototype in
February 2001 and has finished much of the design, fabrication and assembly of
the initial prototype. Based on the work remaining to be completed, the Company
expects Altaire Systems to finish the initial prototype for testing during the
second quarter of 2004. The funds to pay Altaire Systems have and will come from
the I&I grant money.

         The Company has retained the University of Utah to test and analyze
equipment design and implementation, test working scale models and perform the
needed data analysis and computer modeling once the prototype is fully
functional. The University of Utah will also assess and develop a plan for
commercializing the technology. For these services, the University of Utah will
receive an estimated total of $104,968. The funds to pay for these services have
and will come from the I&I research grant received by the Company.

         As of September 30, 2003, the Company had spent approximately $140,137
of the I&I grant money. Of the approximately $58,863 of I&I grant money
remaining, the Company expects to expend $57,319 to the University of Utah, $102
to Altaire and $1,442 on grant related travel.

         The Company anticipates that the prototype will be fully operational
during the second quarter of 2004. The Company does not plan to market or
manufacture the equipment. Rather, it plans to research, develop and test the
prototype. If and when testing proves to be successful, the Company will seek to
license the technology for marketing and manufacture. The Company expects that
the prototype will work in smaller commercial settings.

         It is the Company's intent to pursue outside sources through licensing
agreements to market and exploit the commercial applications of this technology.
To date, however, the Company has made limited contacts with outside sources and
no firm commitments or license arrangements are in place.

         The Company believes it can satisfy its current cash requirements for
the next twelve months from the remaining proceeds of the I&I grant and from
funds provided under the Private Equity Credit Agreement with Techgrand.

                                       11
<PAGE>

         In addition, the Company has been invited by the DOE to make
application for the DOE NICE(3) grant in conjunction with the Utah Engineering
Experiment Station at the University of Utah and the University's industry
partners in Utah. The NICE(3) grant is a cost sharing program for projects that
develop and demonstrate advances in energy efficient and clean production
technologies. To date the Company has not actively pursued this grant because it
has been unsuccessful in finding an industry partner. The Company will continue
to seek an industry partner, and when an appropriate partner is found, the
Company intends to make application for the NICE3 grant.

Item 3.  Controls and Procedures

         (a) Evaluation of Disclosure Controls and Procedures. The Company's
Chief Executive Officer and Chief Financial Officer have conducted an evaluation
of the Company's disclosure controls and procedures as of a date (the
"Evaluation Date") within 90 days before the filing of this quarterly report.
Based on their evaluation, the Company's Chief Executive Officer and Chief
Financial Officer have concluded that the Company's disclosure controls and
procedures are effective to ensure that information required to be disclosed by
the Company in reports that it files or submits under the Securities Exchange
Act of 1934 is recorded, processed, summarized and reported within the time
periods specified in the applicable Securities and Exchange Commission rules and
forms.

         (b) Changes in Internal Controls and Procedures. Subsequent to the
Evaluation Date, there were no significant changes in the Company's internal
controls or in other factors that could significantly affect these controls, nor
were any corrective actions required with regard to significant deficiencies and
material weaknesses.

                           PART II - OTHER INFORMATION

Item 5.  Other Information

         During the quarter, the Board of Directors of the Company appointed
Jennifer Preece as the Chief Financial Officer of the Company. Mrs. Preece is
currently and has been employed as a commercial real estate agent in Salt Lake
City, Utah since 1999. At this time, Mrs. Preece intends to maintain her current
full-time employment as a commercial real estate agent in addition to the
services she will provide the Company. Prior to her employment as a Commercial
Real Estate Agent, Mrs. Preece worked from 1998 to 1999 as a marketing
specialist for a real estate broker. Mrs. Preece earned a B.S. degree in
Economics from the University of Utah in May 2003. Mrs. Preece is 23 years old.

                                       12
<PAGE>

Item 6.  Exhibits and Reports on Form 8-K

         (A) Reports on Form 8-K

                  None.

         (B) Exhibits. The following exhibits are included as part of this
report:

Exhibit No.      Exhibit                                         Location
-----------      -------                                         --------

Exhibit 10.1     Private Equity Credit Agreement                 Attached hereto

Exhibit 31.1     Certification of Principal Executive Officer    Attached hereto

Exhibit 31.2     Certification of Principal Financial Officer    Attached hereto

Exhibit 32.1     Certification Pursuant to Section 906           Attached hereto
                 of the Sarbanes-Oxley Act of 2002


                                   SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this to be signed on its behalf by the undersigned
thereunto duly authorized.

                                         EMPS Research Corporation



November 14, 2003                        By: /s/ Louis Naegle
                                            ------------------------------------
                                            Louis Naegle,
                                            Principal Executive Officer



November 14, 2003                        By: /s/ Jennifer Preece
                                            ------------------------------------
                                            Jennifer Preece,
                                            Principal Financial Officer

                                       13